Natural Killer Cells

[Celularity, Inc. (GlobenewsWire, Inc.)] Celularity Inc. announced the US FDA has cleared its Investigational New Drug application for the use of CYNK-101 in combination with standard chemotherapy, trastuzumab and pembrolizumab in patients with first-line locally advanced unresectable or metastatic HER2/neu positive gastric or gastroesophageal junction adenocarcinoma.

[Proceedings of the National Academy of Sciences of the United States of America] Using Zfp683 reporter mice, scientists showed that correlation of Hobit expression with type 1 innate lymphoid cells was tissue- and context-dependent.

[Oncogene] Scientists found that the 18fluoro-deoxyglucose positron emission tomography/computed tomography-based markers were positively associated with the expression of programmed cell death ligand 1, pyruvate kinase M2, both of which indicate poor prognosis in patients with pancreatic ductal adenocarcinoma.

[Stem Cell Research & Therapy] NK cells have always been thought to be short-lived and with no antigen specificity; however, recent data supports the presence of NK cell memory including in the hapten-specific contact hypersensitivity model and in certain viral infections.

[Current Opinion in Immunology] Investigators offer a brief review of new insights into human NK cell diversity specifically defined by next generation sequencing and single-cell transcriptomic studies.

[Molecular Therapy-Oncolytics] Scientists overview and discuss this new perspective, focusing on the most relevant candidates for this role among the variety of potential NK immune checkpoints.